8-KOther Events

BRISTOL MYERS SQUIBB CO 8-K Report (Jan 25, 2001)

Filed January 25, 2001For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K report on January 24, 2001, detailing significant financial restatements and providing audited financial statements for the years ending December 31, 1999, 1998, and 1997. A key event leading to these restatements was the announced divestiture of its Clairol and Zimmer businesses, which have been presented as discontinued operations. The report includes detailed five-year financial summaries, balance sheets, statements of earnings, comprehensive income, and cash flows. Investors will find the financial performance data, including net sales, earnings from continuing operations, and earnings per share, to be particularly relevant. The company also provided insights into its business segments, detailing performance by Medicines, Beauty Care, Nutritionals, and Medical Devices, with the Medicines segment being the largest contributor to both sales and earnings. The filing also addresses significant legal matters, including ongoing litigation related to breast implants and prescription drug pricing.

Key Highlights

  • 1Bristol-Myers Squibb Company (BMY) has restated its financial statements to present the Clairol and Zimmer businesses as discontinued operations, following their planned divestitures announced on September 28, 2000.
  • 2The report includes audited consolidated financial statements for the years ended December 31, 1999, 1998, and 1997, offering a comprehensive view of the company's financial performance.
  • 3A five-year financial summary highlights steady growth in Net Sales, increasing from $11,320 million in 1995 to $16,878 million in 1999.
  • 4Earnings from Continuing Operations show a significant increase from $1,517 million in 1995 to $3,789 million in 1999, demonstrating strong operational performance.
  • 5The company is actively managing its business portfolio, with the divestiture of non-core assets and a strategic focus on its core businesses.
  • 6The filing includes detailed segment information, showing the Medicines segment as the largest contributor to both Net Sales and Earnings Before Taxes.
  • 7Significant legal matters, including breast implant litigation and prescription drug pricing challenges, are disclosed, with the company believing they will not have a material adverse effect on its financial position.

Frequently Asked Questions

The main purpose of this 8-K filing is to report the restatement of Bristol-Myers Squibb Company's financial statements due to the planned divestiture of its Clairol and Zimmer businesses, which are now presented as discontinued operations. It also provides audited consolidated financial statements for the years 1997-1999.

The five-year summary (1995-1999) shows a consistent upward trend in Net Sales, growing from $11.3 billion to $16.9 billion. Earnings from Continuing Operations also saw substantial growth, increasing from $1.5 billion to $3.8 billion. This indicates strong operational performance and revenue expansion over the period.

The divestiture means that the financial results of Clairol and Zimmer will be reported as 'discontinued operations' in the company's financial statements. This reclassification allows investors to better assess the performance of the ongoing 'continuing operations' and provides historical data that is consistent with this strategic shift.

The major business segments identified are Medicines, Beauty Care, Nutritionals, and Medical Devices. The Medicines segment is the most significant, contributing the largest portion of both Net Sales and Earnings Before Taxes, indicating its strategic importance to the company.